A Study of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis (ICONIC-ADVANCE 2)

Recruitment Status
ACTIVE, NOT RECRUITING
(See Contacts and Locations)Verified February 2026 by Janssen Research & Development, LLC
Sponsor
Janssen Research & Development, LLC
Information Provided by (Responsible Party)
Janssen Research & Development, LLC
Clinicaltrials.gov Identifier
NCT06220604
Other Study ID Numbers:
77242113PSO3004
First Submitted
January 14, 2024
First Posted
January 23, 2024
Last Update Posted
March 11, 2026
Last Verified
February 2026

ClinicalTrials.gov processed this data on March 2026. Link to the current ClinicalTrials.gov record .

History of Changes

Study Details

Study Description

Condition or DiseaseIntervention/Treatment
Plaque Psoriasis
Drug: JNJ-77242113Drug: JNJ-77242113Drug: JNJ-77242113

Study Design

Study TypeInterventional
Actual Enrollment731 participants
Design AllocationRandomized
Interventional ModelParallel Assignment
MaskingDouble
Primary PurposeTreatment
Official TitleA Phase 3 Multicenter, Randomized, Double-blind, Placebo-controlled and Deucravacitinib Active Comparator-controlled Study to Evaluate the Efficacy and Safety of JNJ-77242113 for the Treatment of Participants With Moderate to Severe Plaque Psoriasis
Study Start DateMarch 8, 2024
Actual Primary Completion DateNovember 14, 2024
Actual Study Completion Date1yr 3mos from now

Groups and Cohorts

Group/CohortIntervention/Treatment
JNJ-77242113
Participants will receive JNJ-77242113 from Week 0 through Week 156 and deucravacitinib matching placebo from Week 0 through Week 24.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.
Placebo
Participants will receive matching placebo for JNJ-77242113 from Week 0 through Week 16, matching placebo for deucravacitinib from Week 0 through Week 24 and JNJ-77242113 from Week 16 through Week 156.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.
Deucravacitinib
Participants will receive deucravacitinib from Week 0 through Week 24 and matching placebo for JNJ-77242113 from Week 0 through Week 24 and JNJ-77242113 from Week 24 through Week 156.
Drug: JNJ-77242113
JNJ-77242113 will be administered orally.

Outcome Measures

Primary Outcome Measures
  1. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an Investigator's Global Assessment (IGA) Score of 0 or 1 and Greater Than or Equal to (>=) 2 Grade Improvement From Baseline at Week 16
    Percentage of participants achieving an IGA score of 0 or 1 and \>=2 grade improvement from baseline at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  2. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Area and Severity Index (PASI) 90 Response at Week 16
    Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
Secondary Outcome Measures
  1. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving an IGA Score of 0 at Week 16
    Percentage of participants achieving an IGA Score of 0 at Week 16 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4)
  2. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 75 Response at Weeks 4 and 16
    Percentage of participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Weeks 4 and 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  3. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 90 Response at Week 8
    Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Week 8 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  4. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving PASI 100 Response at Week 16
    Percentage of participants achieving PASI 100 response (100% improvement in PASI from baseline) at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  5. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Scalp-specific Investigator Global Assessment (ss-IGA) Score of 0 or 1 and a >=2-grade Improvement From Baseline at Week 16
    Percentage of participants achieving ss-IGA score of 0 or 1 and a \>=2-grade improvement from baseline at Week 16 will be reported. The ss-IGA instrument is used to evaluate the disease severity of scalp psoriasis. The lesions are assessed in terms of the clinical signs of redness, thickness, and scaliness which are scored as: absence of disease (0), very mild disease (1), mild disease (2), moderate disease (3), and severe disease (4).
  6. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Psoriasis Symptom and Sign Diary (PSSD) Symptoms Score of 0 at Weeks 8 and 16
    Percentage of participants achieving PSSD symptoms score of 0 at Weeks 8 and 16 will be reported. The PSSD is a self-administered patient-reported outcome (PRO) instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  7. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving >=4 Point Improvement From Baseline in PSSD Itch Score at Weeks 4 and 16
    Percentage of participants achieving \>=4 Point improvement from baseline in PSSD itch score at Weeks 4 and 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  8. JNJ-77242113 and Deucravacitinib Group: : Percentage of Participants Achieving an IGA Score of 0 or 1 and >=2 Grade Improvement From Baseline at Weeks 16 and 24
    Percentage of participants who achieve an IGA score of 0 or 1 and \>=2 grade improvement from baseline at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  9. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving an IGA Score of 0 at Weeks 16 and 24
    Percentage of participants who achieve an IGA score of 0 at Weeks 16 and 24 will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
  10. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 75 Response at Weeks 16 and 24
    Percentage of participants achieving PASI 75 response (\>=75% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  11. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 90 Response at Weeks 16 and 24
    Percentage of participants achieving PASI 90 response (\>=90% improvement in PASI from baseline) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  12. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PASI 100 Response at Weeks 16 and 24
    Percentage of participants achieving PASI 100 response (\>=100% improvement in PASI) at Weeks 16 and 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  13. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants With PSSD Symptom Score of 0 at Week 16
    Percentage of participants achieving PSSD symptom score 0 at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  14. Number of Participants with Adverse Events (AEs)
    An adverse event (AE) is any untoward medical event that occurs in a participant administered an investigational product, and it does not necessarily indicate only events with clear causal relationship with the relevant investigational product.
  15. Number of Participants with Serious Adverse Events (SAEs)
    SAEs are any AE which results in death, is life-threatening, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, is a congenital anomaly/birth defect, is a suspected transmission of any infectious agent via a medicinal product, or is medically important.
  16. Change From Baseline in Body Surface Area (BSA) at Week 16
    Change from baseline in BSA at Week 16 will be reported. BSA is a commonly used measure of extent of skin disease. It is defined as the percentage of surface area of the body involved with the condition being assessed (that is, plaque psoriasis).
  17. Change from Baseline in PASI Score at Week 16
    Change from baseline in PASI score at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas are assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  18. Percent Improvement in PASI Score From Baseline at Week 16
    Percent improvement in PASI score from Baseline at Week 16 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  19. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Static Physician's Global Assessment of Genitalia (sPGA-G) Score of 0 or 1 and >=2-grade Improvement From Baseline to Week 16
    Percentage of participants achieving a sPGA-G Score of 0 or 1 and \>=2-grade improvement from baseline to Week 16 will be reported. The sPGA-G is a 6-point scale to assess the severity of genital psoriasis at a given time point. The sPGA-G evaluates erythema, plaque elevation, and scale of genital psoriatic lesions. The severity of genital psoriasis is assessed as clear (0), minimal (1), mild (2), moderate (3), severe (4), and very severe (5).
  20. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving a Physician's Global Assessment of Hands and Feet (hf-PGA) Score of 0 or 1 and at Least a 2-grade Improvement From Baseline to Week 16
    Percentage of participants achieving a hf-PGA score of 0 or 1 and at least a 2-grade improvement from baseline to Week 16 will be reported. The hf-PGA assesses the severity of hand and foot psoriasis using a 5-point scale to score the plaques on the hands and feet as: clear (0), almost clear (1), mild (2), moderate (3), and severe (4).
  21. JNJ-77242113 and Placebo Group: Percent Change From Baseline in Modified Nail Psoriasis Severity Index (mNAPSI) Score at Week 16
    Percent change from baseline in mNAPSI score at Week 16 will be reported. The mNAPSI is an index used for assessing and grading the severity of nail psoriasis. Each of the participant's 10 fingernails are evaluated for 7 features. The first 3 features are each scored from 0 to 3 in severity and are (1) onycholysis and oil-drop dyschromia, (2) pitting, and (3) nail plate crumbling. The next 4 features are scored 0 - absent or 1 - present and are (1) leukonychia, (2) splinter hemorrhages, (3) nail bed hyperkeratosis, and (4) red spots in the lunula. The score ranges from 0 to 13 per nail and 0 to 130 for all fingernails.
  22. JNJ-77242113 and Placebo Group: Percent of Participants Achieving Fingernail Physician's Global Assessment (f-PGA) Score of 0 or 1 at Week 16
    Percent of participants achieving f-PGA score of 0 or 1 at Week 16 will be reported. The f-PGA is used to evaluate the current status of a participant's fingernail psoriasis on a scale of 0 to 4 (clear \[0\], minimal \[1\], mild \[2\], moderate \[3\], or severe \[4\]).
  23. JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Symptom Score at Week 16
    Change from baseline in PSSD symptom score at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  24. JNJ-77242113 and Placebo Group: Change From Baseline in PSSD Sign Score at Week 16
    Change from baseline in PSSD sign score at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  25. JNJ-77242113 and Placebo Group: Percentage of Participants With PSSD Sign Score of 0 at Week 16
    Percentage of participants with PSSD sign score of 0 at Week 16 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  26. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Genital Psoriasis Sexual Frequency Questionnaire (GenPs-SFQ) Item 2 Score of 0 or 1 at Week 16
    Percentage of participants achieving GenPs-SFQ Item 2 score of 0 or 1 at Week 16 will be reported. The GenPs-SFQ is a 2-item participant-reported instrument used to assess the impact of genital psoriasis on the frequency of sexual activity in the last 7 days. Item 1 assesses overall frequency of sexual activity in the last 7 days (none/zero, once, or 2 or more times), and item 2 assesses how frequently genital psoriasis symptoms have limited the frequency of sexual activity in the last 7 days (never \[0\], rarely \[1\], sometimes \[2\], often \[3\], or always \[4\]).
  27. JNJ-77242113 and Placebo Group: Percentage of Participants Achieving Dermatology Life Quality Index (DLQI) Total Score of 0 or 1 at Week 16
    Percentage of participants achieving DLQI total score of 0 or 1 at Week 16 will be reported. The DLQI is a dermatology specific health-related quality of life (HRQoL) instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  28. JNJ-77242113 and Placebo Group: Change From Baseline in Total DLQI Score at Week 16
    Change from baseline in total DLQI score at Week 16 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  29. JNJ-77242113 and Placebo Group: Change from Baseline in Domain Scores of the Patient-reported Outcomes Measurement Information System-29 (PROMIS-29) Score at Week 16
    Change from baseline in domain scores of the PROMIS-29 score at Week 16 will be reported. The PROMIS-29 is a 29-item generic HRQoL survey, assessing each of the 7 PROMIS domains (depression, anxiety, physical function, pain interference, fatigue, sleep disturbance, and ability to participate in social roles and activities) with 4 questions for each domain. The questions are ranked on a 5-point Likert scale. There is also a numerical rating scale that ranges from 0 (No pain) to 10 (Worst pain imaginable) for pain intensity. The raw domain scores are converted to standardized T-scores with a mean of 50 and a standard deviation of 10. Higher scores on anxiety, depression, fatigue, sleep disturbance, and pain interference indicate more severe symptoms. Higher scores on physical function and social participation indicate better health outcomes.
  30. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving DLQI Score of 0 or 1 at Weeks 16 and 24
    Percentage of participants achieving DLQI score of 0 or 1 at Weeks 16 and 24 will be reported. The DLQI is a dermatology specific HRQoL instrument designed to assess the impact of the disease on a participant's HRQoL. It is a 10-item questionnaire that assesses HRQoL over the past week and in addition to evaluating overall HRQoL, can be used to assess 6 different aspects that may affect quality of life: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. The total score ranges from 0 to 30 with a higher score indicating greater impact on HRQoL.
  31. JNJ-77242113 and Deucravacitinib Group: Percentage of Participants Achieving PSSD Symptom Score of 0 at Week 24
    Percentage of participants achieving PSSD symptom score of 0 at Week 24 will be reported. The PSSD is a self-administered PRO instrument that includes 11 items covering symptoms (itch, pain, stinging, burning, and skin tightness) and patient-observable signs (skin dryness, cracking, scaling, shedding or flaking, redness, and bleeding) using 0 to 10 numerical rating scales for severity. Two sub scores will be derived each ranging from 0 to 100: the psoriasis symptom score and the psoriasis sign score. A higher score indicates more severe disease.
  32. Percentage of Participants Who Achieve PASI 75 Response After Week 24 Among PASI 75 Non-responders to Deucravacitinib at Week 24
    Percentage of participants who achieve PASI 75 response (\>=75% improvement in PASI) after Week 24 among PASI 75 Non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  33. Percentage of Participants Who Achieve PASI 90 Response After Week 24 Among PASI 90 Non-responders to Deucravacitinib at Week 24
    Percentage of participants who achieve PASI 90 response (\>=90% improvement in PASI) after Week 24 among PASI 90 non-responders to deucravacitinib at Week 24 will be reported. The PASI is a system used for assessing and grading the severity of psoriatic lesions and their response to therapy. In the PASI system, the body is divided into 4 regions: the head, trunk, upper extremities, and lower extremities. Each of these areas is assessed and scored separately for erythema, induration, and scaling, which are each rated on a scale of 0 to 4 and extent of involvement on a scale of 0 to 6. The PASI produces a numeric score that can range from 0 to 72. A higher score indicates more severe disease.
  34. Percentage of Participants Achieving IGA Score of 0 or 1 after Week 24, Among Participants with IGA score >=2 at Week 24 in the Deucravacitinib Group
    Percentage of participants achieving IGA score of 0 or 1 after Week 24, among participants with IGA score \>=2 at Week 24 in the deucravacitinib group will be reported. The IGA documents the investigator's assessment of the participants psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's psoriasis is assessed as cleared (0), minimal (1), mild (2), moderate (3), or severe (4).

Eligibility Criteria

Ages Eligible for Study(Adult, Older Adult)
Sexes Eligible for StudyAll
Accepts Healthy VolunteersNo
Inclusion Criteria
Diagnosis of plaque psoriasis, with or without psoriatic arthritis (PsA), for at least 26 weeks prior to the first administration of study intervention
Total body surface area (BSA) greater than or equal to (\>=)10 percent (%) at screening and baseline
Total psoriasis area and severity index (PASI) \>=12 at screening and baseline
Total investigator global assessment (IGA) \>=3 at screening and baseline
Candidate for phototherapy or systemic treatment for plaque psoriasis
Exclusion Criteria
Nonplaque form of psoriasis (for example, erythrodermic, guttate, or pustular)
Current drug-induced psoriasis (for example, a new onset of psoriasis or an exacerbation of psoriasis from beta blockers, calcium channel blockers, or lithium)
A current diagnosis or signs or symptoms of severe, progressive, or uncontrolled renal, liver, cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
Known allergies, hypersensitivity, or intolerance to JNJ-77242113, deucravacitinib or to any of the excipients or components of the study intervention
Major surgical procedure, (for example, requiring general anesthesia) within 8 weeks before screening, or will not have fully recovered from surgical procedure, or has a surgical procedure planned during the time the participant is expected to participate in the study

Contacts and Locations

Sponsors and CollaboratorsJanssen Research & Development, LLC
Locations
Alliance Dermatology and MOHS Center P C | Phoenix Arizona, United States, 85032California Dermatology & Clinical Research Institute | Encinitas California, United States, 92024T Joseph Raoof Md Inc | Encino California, United States, 91436UCSF Fresno | Fresno California, United States, 93701University of California Los Angeles - Division of Dermatology | Los Angeles California, United States, 90024Wallace Medical Group, Inc | Los Angeles California, United States, 90056Dermatologist Medical Group of North County, Inc. | Oceanside California, United States, 92056Miami Dermatology And Laser Institute | Miami Florida, United States, 33133Bioclinical Research Alliance Inc. | Miami Florida, United States, 33155Forcare Clinical Research Inc | Tampa Florida, United States, 33613Southeast Dermatology Specialists | Douglasville Georgia, United States, 30135Arlington Dermatology | Rolling Meadows Illinois, United States, 60008Skin Sciences, PLLC | Louisville Kentucky, United States, 40217Qualmedica Research | Owensboro Kentucky, United States, 42301DermAssociates, PC | Rockville Maryland, United States, 20850Metro Boston Clinical Partners | Brighton Massachusetts, United States, 02135ActivMed Practices and Research | Methuen Massachusetts, United States, 01844University of Michigan | Ann Arbor Michigan, United States, 48109Great Lakes Research Group | Bay City Michigan, United States, 48706The Derm Institute of West Michigan | Caledonia Michigan, United States, 49316Hamzavi Dermatology | Canton Michigan, United States, 48187Somerset Skin Centre | Troy Michigan, United States, 48084Cleaver Dermatology | Kirksville Missouri, United States, 63501Bexley dermatology research | Bexley Ohio, United States, 43209Essential Medical Research | Tulsa Oklahoma, United States, 74137Oregon Dermatology & Research Center | Portland Oregon, United States, 97210-2996Paddington Testing Co, Inc. | Philadelphia Pennsylvania, United States, 19103Clinical Research Center of the Carolinas LLC | Charleston South Carolina, United States, 29407Palmetto Clinical Trial Services, LLC | Greenville South Carolina, United States, 29615Arlington Research Center, Inc. | Arlington Texas, United States, 76011UT Southwestern Medical Center | Dallas Texas, United States, 75390Dermatology Clinical Research Center of San Antonio | San Antonio Texas, United States, 78229Center for Clinical Studies | Webster Texas, United States, 77598Cope Family Medicine - Ogden Clinic | Bountiful Utah, United States, 84010Springville Dermatology CCT Research | Springville Utah, United States, 84663Kalo Clinical Research | West Valley City Utah, United States, 84120Virginia Dermatology Skin Cancer Center Pllc | Norfolk Virginia, United States, 23502The Skin Centre | Benowa , Australia, 4217Monash Medical Centre | Clayton , Australia, 3168Premier Specialists | Kogarah , Australia, 2217The Alfred Hospital | Melbourne , Australia, 3004ISHI dermatology | Mitcham , Australia, 3132Royal Melbourne Hospital | Parkville , Australia, 3050UNESP - Faculdade de Medicina da Universidade Estadual Paulista - Campus Botucatu | Botucatu , Brazil, 18618-687Chronos Clinica Medica LTDA Chronos Pesquisa Clinica | Brasília , Brazil, 72.145-450Hospital Das Clinicas Da Faculdade De Medicina De RPUSP HCRP | Ribeirão Preto , Brazil, 14048 900Fundacao do ABC Centro Universitario FMABC | Santo André , Brazil, 09060 870Fundacao Faculdade Regional De Medicina S Jose Rio Preto Hospital De Base | São José do Rio Preto , Brazil, 15090 000Hospital Das Clinicas Da Faculdade De Medicina Da USP | São Paulo , Brazil, 05403 900Dr. Chih ho Hong Medical | Surrey British Columbia, Canada, V3R 6A7Wiseman Dermatology Research Inc. | Winnipeg Manitoba, Canada, R3M 3Z4Lovegrove Dermatology | London Ontario, Canada, N6A 5R9Lynderm Research Inc. | Markham Ontario, Canada, L3P 1X2DermEdge Research | Mississauga Ontario, Canada, L4Y 4C5Skin Centre for Dermatology | Peterborough Ontario, Canada, K9J 5K2North York Research Inc | Toronto Ontario, Canada, M2N 3A6Toronto Research Centre | Toronto Ontario, Canada, M3H 5Y8XLR8 Medical Research | Windsor Ontario, Canada, N8T 1E6Innovaderm Research Inc. | Montreal Quebec, Canada, H2X 2V1Centre De Recherche Dermatologique Du Quebec Metropolitain | Québec Quebec, Canada, G1V 4X7Hautarztpraxis Dr. Mihaescu | Augsburg , Germany, 86150Fachklinik Bad Bentheim | Bad Bentheim , Germany, 48455CRS Clinical Research Services Berlin GmbH | Berlin , Germany, 13627Niesmann & Othlinghaus GbR | Bochum , Germany, 44793Klinikum Darmstadt GmbH - Hautklinik | Darmstadt , Germany, 64283Medizinische Fakultaet Carl Gustav Carus Technische Universitaet Dresden | Dresden , Germany, 01307Hautzentrum Dulmen | Dülmen , Germany, 48249Privatpraxis Dr. Hilton & Partner | Düsseldorf , Germany, 40212Derma-Study-Center Friedrichshafen GmbH | Friedrichshafen , Germany, 88045Eurofins bioskin GmbH | Hamburg , Germany, 20095Universitaetsklinikum Heidelberg | Heidelberg , Germany, 69120Hautarztpraxis | Mahlow , Germany, 15831Universitatsmedizin der Johannes Gutenberg Universitat Mainz | Mainz , Germany, 55131Hautmedizin Saar Science Hms GmbH | Merzig , Germany, 66663Universitaetsklinikum Muenster | Münster , Germany, 48149Klinikum Oldenburg | Oldenburg , Germany, 26133Hautarztpraxis 1 | Witten , Germany, 58453CentroDerm GmbH | Wuppertal , Germany, 42287Uno Medical Trials Ltd. | Budapest , Hungary, 1152Bugat Pal Korhaz | Gyöngyös , Hungary, 3200Synexus Magyarorszag Kft | Gyula , Hungary, 5700Bacs Kiskun Varmegyei Oktatokorhaz | Kecskemét , Hungary, 6000Synexus Magyarorszag Kft 1 | Zalaegerszeg , Hungary, H-8900Renew Clinic | Bialystok , Poland, 15 797Care Clinic | Katowice , Poland, 40 568Centrum Medyczne Angelius Provita | Katowice , Poland, 40 611Prywatny Gabinet Dermatologiczny Elzbieta Klujszo | Kielce , Poland, 25-316SGD s.c. | Krakow , Poland, 30-002Krakowskie Centrum Badan Klinicznych | Krakow , Poland, 30-303Jagiellonskie Centrum Innowacji | Krakow , Poland, 30-348Diamond Clinic | Krakow , Poland, 31 559Etyka Osrodek Badan Klinicznych | Olsztyn , Poland, 10-117Carpe Diem Centrum Medycyny Estetycznej | Warsaw , Poland, 02 661Synexus Polska Sp z o o Oddzial w Warszawie | Warsaw , Poland, 02 672Royalderm Agnieszka Nawrocka | Warsaw , Poland, 02-962WroMedica I Bielicka A Strzalkowska s c | Wroclaw , Poland, 51 685Cabinet Medical Dermato-Venerologie | Cluj-Napoca , Romania, 400105Centrul Medical Vitaplus | Craiova , Romania, 200541Spitalul Clinic Judetean de Urgenta | Craiova , Romania, 200642Sc Iasiprest Srl | Iași , Romania, 700381Spitalul Clinic Judetean de Urgenta Bihor | Oradea , Romania, 410167Spitalul Clinic Judetean Mures | Târgu Mureş , Romania, 540342New Derm Clinic | Timișoara , Romania, 300757Korea University Ansan Hospital | Ansan-si , South Korea, 15355Hallym University Sacred Heart Hospital | Anyang-si , South Korea, 14068The Catholic University of Korea Bucheon St Mary s Hospital | Bucheon-si , South Korea, 14647Chosun university hospital | Gwangju , South Korea, 61453CHA Bundang Medical Center, CHA University | Seongnam , South Korea, 13496Asan Medical Center | Seoul , South Korea, 05505Korea University Guro Hospital | Seoul , South Korea, 8308Hosp. Univ. Fundacion Alcorcon | Alcorcón , Spain, 28922Hosp. Univ. Germans Trias I Pujol | Badalona , Spain, 08916Hosp Clinic de Barcelona | Barcelona , Spain, 08036Hosp. de Manises | Manises , Spain, 46940Hosp Clinico Univ de Salamanca | Salamanca , Spain, 37007Clinica Gaias | Santiago de Compostela , Spain, 15702Hosp. Clinico Univ. de Santiago | Santiago de Compostela , Spain, 15706Hosp. Virgen Macarena | Seville , Spain, 41009Hosp. Ntra. Sra. de Valme | Seville , Spain, 41014Hosp. de La Marina Baixa | Villajoyosa , Spain, 03570Hosp. Clinico Univ. Lozano Blesa | Zaragoza , Spain, 50009Kaohsiung Medical University Chung Ho Memorial Hospital | Kaohsiung City , Taiwan, 80756Kaohsiung Veterans General Hospital | Kaohsiung City , Taiwan, 81362Chung Shan Medical University Hospital | Taichung , Taiwan, 40201Taichung Veterans General Hospital | Taichung , Taiwan, 40705National Cheng Kung University Hospital | Tainan , Taiwan, 710Taipei Medical University | Taipei , Taiwan, 110Taipei Municipal Wanfang Hospital | Taipei , Taiwan, 116
Investigators
Study Director: Janssen Research & Development, LLC Clinicaltrial, Janssen Research & Development, LLC